Compare Stocks: RCUS, EXEL, ARWR, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$89.59 +4.2%	$79.26	$15.01 ▼ $95.49	$12.12B	1.27	2.29 million shs	2.03 million shs
BMRN BioMarin Pharmaceutical	$60.72 +1.2%	$57.74	$49.26 ▼ $66.28	$11.60B	0.24	1.60 million shs	1.24 million shs
EXEL Exelixis	$56.00 +1.7%	$53.83	$33.76 ▼ $57.57	$13.84B	0.44	2.39 million shs	2.73 million shs
RCUS Arcus Biosciences	$28.81 +4.3%	$27.09	$8.88 ▼ $31.74	$3.47B	0.8	1.02 million shs	845,208 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.61%	+0.56%	+2.41%	+14.79%	+439.92%
BMRN BioMarin Pharmaceutical	-0.05%	-0.46%	+1.70%	+12.68%	+3.18%
EXEL Exelixis	+3.83%	-1.34%	-1.41%	+23.95%	+47.77%
RCUS Arcus Biosciences	-1.69%	-1.02%	-8.94%	+6.20%	+202.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$89.59 +4.2%	$79.26	$15.01 ▼ $95.49	$12.12B	1.27	2.29 million shs	2.03 million shs
BMRN BioMarin Pharmaceutical	$60.72 +1.2%	$57.74	$49.26 ▼ $66.28	$11.60B	0.24	1.60 million shs	1.24 million shs
EXEL Exelixis	$56.00 +1.7%	$53.83	$33.76 ▼ $57.57	$13.84B	0.44	2.39 million shs	2.73 million shs
RCUS Arcus Biosciences	$28.81 +4.3%	$27.09	$8.88 ▼ $31.74	$3.47B	0.8	1.02 million shs	845,208 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.61%	+0.56%	+2.41%	+14.79%	+439.92%
BMRN BioMarin Pharmaceutical	-0.05%	-0.46%	+1.70%	+12.68%	+3.18%
EXEL Exelixis	+3.83%	-1.34%	-1.41%	+23.95%	+47.77%
RCUS Arcus Biosciences	-1.69%	-1.02%	-8.94%	+6.20%	+202.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$96.92	8.18% Upside
BMRN BioMarin Pharmaceutical	2.71	Moderate Buy	$88.26	45.36% Upside
EXEL Exelixis	2.37	Hold	$49.50	-11.61% Downside
RCUS Arcus Biosciences	2.58	Moderate Buy	$36.40	26.34% Upside

Current Analyst Ratings Breakdown

Latest RCUS, EXEL, ARWR, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	EXEL Exelixis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
7/30/2026	ARWR Arrowhead Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$101.00 ➝ $123.00
7/27/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$100.00 ➝ $115.00
7/24/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B+) ➝ Buy (B)
7/23/2026	EXEL Exelixis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$50.00 ➝ $53.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$100.00 ➝ $120.00
7/23/2026	ARWR Arrowhead Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00 ➝ $126.00
7/22/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/22/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$90.00 ➝ $115.00
7/20/2026	RCUS Arcus Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $45.00
7/17/2026	RCUS Arcus Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	15.21	$0.12 per share	720.35	$3.64 per share	24.61
BMRN BioMarin Pharmaceutical	$3.22B	3.64	$2.89 per share	21.03	$31.68 per share	1.92
EXEL Exelixis	$2.32B	6.07	$3.08 per share	18.19	$8.06 per share	6.95
RCUS Arcus Biosciences	$247M	14.67	N/A	N/A	$5.84 per share	4.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.15	N/A	N/A	N/A	-48.38%	-55.09%	-18.13%	8/4/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$1.37	29.55	10.79	0.46	8.29%	6.50%	5.07%	8/6/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.01	18.42	15.14	1.59	35.08%	39.89%	30.23%	8/5/2026 (Confirmed)
RCUS Arcus Biosciences	-$353M	-$3.18	N/A	N/A	N/A	-156.36%	-68.97%	-35.27%	8/5/2026 (Estimated)

Latest RCUS, EXEL, ARWR, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.9450	N/A	N/A	N/A	$932.03 million	N/A
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	N/A	N/A	N/A	$636.40 million	N/A
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	N/A	N/A	N/A	$22.22 million	N/A
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
5/7/2026	Q2 2026	ARWR Arrowhead Pharmaceuticals	-$1.0950	-$0.93	+$0.1650	-$0.93	$73.84 million	$73.74 million
5/5/2026	Q1 2026	EXEL Exelixis	$0.75	$0.87	+$0.12	$0.8138	$607.51 million	$610.81 million
5/5/2026	Q1 2026	RCUS Arcus Biosciences	-$0.92	-$1.02	-$0.10	-$1.02	$29.49 million	$17.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.41	6.23	6.23
BMRN BioMarin Pharmaceutical	0.23	5.81	4.20
EXEL Exelixis	N/A	3.26	3.19
RCUS Arcus Biosciences	0.19	4.04	4.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.28 million	191.97 million	Optionable
EXEL Exelixis	1,077	251.35 million	244.82 million	Optionable
RCUS Arcus Biosciences	500	125.77 million	116.21 million	Optionable

RCUS, EXEL, ARWR, and BMRN Headlines

Recent News About These Companies

Earnings To Watch: Arcus Biosciences Inc (RCUS) Q2 2026 -- GF Value Sees 75% Downside

August 4 at 1:01 PM | finance.yahoo.com

Arcus Biosciences, Inc. $RCUS Shares Acquired by Renaissance Technologies LLC

August 3 at 4:48 AM | marketbeat.com

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

July 29, 2026 | globenewswire.com

Arcus Biosciences (RCUS) Projected to Post Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 28, 2026 | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by Analysts

July 28, 2026 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

July 27, 2026 | businesswire.com

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

July 24, 2026 | seekingalpha.com

Knott David M Jr Trims Stake in Arcus Biosciences, Inc. $RCUS

July 24, 2026 | marketbeat.com

Illinois Municipal Retirement Fund Invests $783,000 in Arcus Biosciences, Inc. $RCUS

July 24, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for RCUS Earnings

July 24, 2026 | americanbankingnews.com

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

July 23, 2026 | zacks.com

Decheng Capital LLC Reduces Stock Holdings in Arcus Biosciences, Inc. $RCUS

July 23, 2026 | marketbeat.com

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

July 22, 2026 | businesswire.com

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

July 22, 2026 | businesswire.com

What is HC Wainwright's Forecast for RCUS FY2029 Earnings?

July 22, 2026 | marketbeat.com

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

July 21, 2026 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Stock Price Up 6.6% on Analyst Upgrade

July 20, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Price Target Raised to $45.00

July 20, 2026 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 20,067 Shares

July 14, 2026 | insidertrades.com

An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

July 13, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, EXEL, ARWR, and BMRN Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$89.59 +3.58 (+4.16%)

Closing price 04:00 PM Eastern

Extended Trading

$88.85 -0.74 (-0.82%)

As of 07:47 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$60.72 +0.73 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$59.50 -1.22 (-2.01%)

As of 07:34 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$56.00 +0.94 (+1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$56.33 +0.33 (+0.59%)

As of 07:59 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Arcus Biosciences NYSE:RCUS

$28.81 +1.19 (+4.31%)

Closing price 03:59 PM Eastern

Extended Trading

$28.93 +0.12 (+0.41%)

As of 07:34 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, EXEL, ARWR, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, EXEL, ARWR, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, EXEL, ARWR, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, EXEL, ARWR, and BMRN Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCUS, EXEL, ARWR, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCUS, EXEL, ARWR, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCUS, EXEL, ARWR, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, EXEL, ARWR, and BMRN Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools